Skip to content

Study · Animal study (in vivo) · rat · 2014

6 results

Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.

Ersan N, van Ruijven LJ, Bronckers AL, Olgaç V, Ilgüy D, Everts V

Dento maxillo facial radiology29 Oct 2013Cited by 30 (Europe PMC)

PMID24170800 (opens in a new tab)PMCIDPMC3887480 (opens in a new tab)DOI10.1259/dmfr.20130144 (opens in a new tab)PepBankPUB-24170800
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with zoledronic acid-induced jaw injury, teriparatide increased new socket bone mineral density compared with zoledronic acid alone.

    In plain wordsIn rats, teriparatide increased new tooth-socket bone density compared with zoledronic acid alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNew bone mineral density
    Study

    ratn = 20

    Sprague-Dawley rats with zoledronic acid-induced jaw osteonecrosis
    Comparator
    zoledronic acid alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    MicroCT (µCT) examination showed that bone mineral density of the newly formed bone in the extraction socket was lower in the ZA group than in the ZA + TP group (p < 0.05).
    2 context sentences
    Summary · context
    Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP.
    Summary · context
    A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with zoledronic acid-induced jaw injury, teriparatide reduced osteonecrotic bone area compared with zoledronic acid alone.

    In plain wordsIn rats, teriparatide reduced the area of dead jaw bone compared with zoledronic acid alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOsteonecrotic bone area
    Study

    ratn = 20

    Sprague-Dawley rats with zoledronic acid-induced jaw osteonecrosis
    Comparator
    zoledronic acid alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Histopathological examination revealed that only the ZA and ZA + TP groups developed osteonecrosis, and the osteonecrotic bone area in the ZA group was larger than that in the ZA + TP group (p < 0.05).
    2 context sentences
    Summary · context
    Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP.
    Summary · context
    A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with zoledronic acid-induced jaw injury, detached osteoclast counts were lower with teriparatide than with zoledronic acid alone.

    In plain wordsIn rats, teriparatide reduced detached bone-resorbing cell counts compared with zoledronic acid alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseDetached osteoclasts
    Study

    ratn = 20

    Sprague-Dawley rats with zoledronic acid-induced jaw osteonecrosis
    Comparator
    zoledronic acid alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tartrate-resistant acid phosphatase (TRAcP) enzyme histochemistry revealed that the number of detached and large osteoclasts were higher in the ZA group than in other groups, whereas
    2 context sentences
    Summary · context
    Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP.
    Summary · context
    A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with zoledronic acid-induced jaw injury, large osteoclast counts were lower with teriparatide than with zoledronic acid alone.

    In plain wordsIn rats, teriparatide reduced large bone-resorbing cell counts compared with zoledronic acid alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseLarge osteoclasts
    Study

    ratn = 20

    Sprague-Dawley rats with zoledronic acid-induced jaw osteonecrosis
    Comparator
    zoledronic acid alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tartrate-resistant acid phosphatase (TRAcP) enzyme histochemistry revealed that the number of detached and large osteoclasts were higher in the ZA group than in other groups, whereas
    2 context sentences
    Summary · context
    Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP.
    Summary · context
    A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats given teriparatide after zoledronic acid-induced jaw injury, no animals had clinically exposed necrotic bone.

    In plain wordsIn rats given teriparatide after zoledronic acid-induced jaw injury, no animals had clinically exposed dead bone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableClinical necrotic bone exposure
    Study

    ratn = 10

    Sprague-Dawley rats with zoledronic acid-induced jaw osteonecrosis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Clinical examination revealed necrotic bone exposure in none of the animals.
    2 context sentences
    Summary · context
    Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP.
    Summary · context
    A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In rats, apoptotic osteoclast counts were higher in both zoledronic acid groups, including the teriparatide group, than in controls.

    In plain wordsIn rats, dying bone-resorbing cell counts were higher in both zoledronic acid groups, including the teriparatide group, than in controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseApoptotic osteoclasts
    Study

    ratn = 20

    Sprague-Dawley rats with zoledronic acid-induced jaw osteonecrosis
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    whereas the number of apoptotic osteoclasts in both ZA and ZA + TP groups were higher than in the control group (p < 0.05).
    2 context sentences
    Summary · context
    Sprague-Dawley rats were divided into three groups: I-zoledronic acid (ZA, n = 10); II-ZA and teriparatide (ZA + TP, n = 10); III-control (n = 10). Osteonecrosis was induced by administering zoledronic acid to groups ZA and ZA + TP.
    Summary · context
    A week after the injections, rats underwent extraction of the first left mandibular molar. Following a four week period, TP was administered to the ZA + TP group for 28 days.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06061354

Teriparatide on Maxillary Sinus Floor Osseointegration

Universidad de Valparaison = 4223 Aug 2023 to est. Dec 2024

Bone Regeneration

Trial pageClinicalTrials.govUpdated 30 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.